| Year |
Citation |
Score |
| 2018 |
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, et al. Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29636357 DOI: 10.1158/1078-0432.Ccr-17-2793 |
0.575 |
|
| 2017 |
Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Vander Griend D, Conzen SD, Szmulewitz RZ. Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. Molecular Cancer Therapeutics. PMID 28428441 DOI: 10.1158/1535-7163.Mct-16-0923 |
0.592 |
|
| 2017 |
Tonsing-Carter E, Bowie K, West D, Harkless R, Hernandez K, Conzen S. Abstract P3-05-09: Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-05-09 |
0.597 |
|
| 2016 |
West DC, Pan D, Tonsing-Carter EY, Hernandez KM, Pierce CF, Styke SC, Bowie KR, Garcia TI, Kocherginsky M, Conzen SD. GR and ER co-activation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Molecular Cancer Research : McR. PMID 27141101 DOI: 10.1158/1541-7786.Mcr-15-0433 |
0.573 |
|
| 2016 |
West D, Hosfield D, Mayne C, Skor M, Styke S, Pierce C, Kocherginsky M, Hunt H, Fleming G, Szmulewitz R, Tajkhorshid E, Greene G, Conzen S. Abstract PD3-02: Second-generation selective glucocorticoid receptor modulators in triple-negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd3-02 |
0.638 |
|
| 2012 |
West DC, Qin Y, Peterson QP, Thomas DL, Palchaudhuri R, Morrison KC, Lucas PW, Palmer AE, Fan TM, Hergenrother PJ. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Molecular Pharmaceutics. 9: 1425-34. PMID 22486564 DOI: 10.1021/Mp200673N |
0.715 |
|
| 2012 |
Hsu DC, Roth HS, West DC, Botham RC, Novotny CJ, Schmid SC, Hergenrother PJ. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1). Acs Combinatorial Science. 14: 44-50. PMID 22007686 DOI: 10.1021/Co2001372 |
0.74 |
|
| 2011 |
Lucas PW, Schmit JM, Peterson QP, West DC, Hsu DC, Novotny CJ, Dirikolu L, Churchwell MI, Doerge DR, Garrett LD, Hergenrother PJ, Fan TM. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. Investigational New Drugs. 29: 901-11. PMID 20499133 DOI: 10.1007/S10637-010-9445-Z |
0.737 |
|
| 2010 |
Peterson QP, Hsu DC, Novotny CJ, West DC, Kim D, Schmit JM, Dirikolu L, Hergenrother PJ, Fan TM. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Research. 70: 7232-41. PMID 20823163 DOI: 10.1158/0008-5472.Can-10-0766 |
0.764 |
|
| 2010 |
Peterson QP, Goode DR, West DC, Botham RC, Hergenrother PJ. Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis. Nature Protocols. 5: 294-302. PMID 20134429 DOI: 10.1038/Nprot.2009.223 |
0.67 |
|
| 2009 |
Peterson QP, Goode DR, West DC, Ramsey KN, Lee JJ, Hergenrother PJ. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. Journal of Molecular Biology. 388: 144-58. PMID 19281821 DOI: 10.1016/J.Jmb.2009.03.003 |
0.752 |
|
| 2009 |
Rosenthal AS, Chen X, Liu JO, West DC, Hergenrother PJ, Shapiro TA, Posner GH. Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. Journal of Medicinal Chemistry. 52: 1198-203. PMID 19186946 DOI: 10.1021/Jm801484V |
0.514 |
|
| Show low-probability matches. |